Aquestive Therapeutics, Inc. (AQST)
$4.67-2.91%Close
SELLRECOVERY · day 4
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $586M
- Beta
- 1.49
- P/E (TTM)
- -7.18
- Short % float
- 30.14%
- Days to cover
- 13.1
- SI change
- +5.8%
- 1W
- +1.30%
- 1M
- -4.30%
- vs SPY 1W
- +1.44%
- vs SPY 1M
- -6.81%
Industry peers
FMP comparable companies · ranked by market cap
- ALKSSELLAlkermes plc$6.8BRECOVERYQ 6$40.26-1.32%
- SUPNBUYSupernus Pharmaceuticals, Inc.$2.5BRECOVERYQ 26$42.81-1.87%
- XERSBUYXeris Biopharma Holdings, Inc.$1.8BBULLQ -1$10.46-2.49%
- AMPHBUYAmphastar Pharmaceuticals, Inc.$1.2BRECOVERYQ 9$26.76-2.65%
- COLLSELLCollegium Pharmaceutical, Inc.$715MBEARQ 14$22.05-2.36%
- ZVRASELLZevra Therapeutics, Inc.$669MCRISISQ -8$11.32-8.22%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on AQST?
- LOPJLB’s latest quantitative signal on Aquestive Therapeutics, Inc. (AQST) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is AQST in?
- Aquestive Therapeutics, Inc. (AQST) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Aquestive Therapeutics, Inc. (AQST) do?
- Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of clobazam for individuals with Lennox-Gastaut syndrome. Suboxone, a sublingual fi…